RJA
MRNA icon

Ross\Johnson & Associates’s Moderna MRNA Stock Holding History

Ross\Johnson & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Hold
2
– – ﹤0.01% 261
2026
Q1 		$102 Hold
2
– – ﹤0.01% 200
2025
Q4 		$59 Hold
2
– – ﹤0.01% 342
2025
Q3 		$52 Hold
2
– – ﹤0.01% 210
2025
Q2 		$55 Hold
2
– – ﹤0.01% 207
2025
Q1 		$57 Buy
+2
New +$71 ﹤0.01% 349

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Ross\Johnson & Associates's MRNA Position: Q2 2026 in Review

Ross\Johnson & Associates held its Moderna (MRNA) position steady in Q2 2026 at 2 shares worth $140. The position accounts for ﹤0.01% of the portfolio, ranked #261.

Ross\Johnson & Associates first reported a position in MRNA in Q1 2025 and has held it in 6 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Ross\Johnson & Associates held 2 shares of Moderna worth $140 as of Q2 2026.
  • Ross\Johnson & Associates left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #261 holding.
  • Ross\Johnson & Associates first reported a position in Moderna in Q1 2025 and has held it in 6 quarters since.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.